Filing Flows › Comparisons › LYEL vs TLPH
Lyell Immunopharma vs Talphera: LYEL and TLPH compared
Lyell Immunopharma is the larger company: $3K of revenue in its latest quarter (Q3 2026) against $1K for Talphera (Q3 2025).
Where the money goes: LYEL and TLPH
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
Talphera (TLPH) · Q3 2025
Talphera, Q3 2025: revenue $1K, net loss $4.4M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Lyell Immunopharma (LYEL) | Talphera (TLPH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2025 |
| Revenue | $3K | $1K |
| Revenue growth, Y/Y | -80% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$45.5M | −$4.4M |
| Operating cash flow | −$34.6M | −$2.5M |
Questions
Which is bigger, Lyell Immunopharma or Talphera?
Lyell Immunopharma is the larger company: $3K of revenue in its latest quarter (Q3 2026) against $1K for Talphera (Q3 2025).
More: Lyell Immunopharma earnings · how Lyell Immunopharma makes money · Talphera earnings · how Talphera makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 12, 2025). Fiscal quarters can end on different dates. Not investment advice.